Carbapenem-producing Enterobacteriaceae CPE average time-to-diagnosis of 48/72 hours. Utilising this CPE work-flow would allow a 'sameday' result. Antimicrobial susceptibility testing results, as is current practice, would remain a 'next-day' result. In conclusion, the Check-Direct CPE ® assay was easily integrated into a local laboratory work-flow and could facilitate a large volume of CPE screening specimens in a single batch, making it cost-effective and convenient for daily CPE testing.
Introduction
Carbapenemase-producing Enterobacteriaceae (CPE) are prevalent worldwide in all areas of healthcare, with isolates and outbreaks reported in acute care facilities [1] [2] [3] [4] including neonatology and paediatrics, 5, 6 respite/convalescence facilities 7 and long-term care facilities. 8 Early detection and infection control strategies are key factors for successfully restricting onward transmission of CPE. 9 The Mid-West of Ireland has the highest rates of CPE in
Ireland with 140 first isolates detected between 2009 and 2015, predominantly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriacea (n=123). 10 For clinicians and antimicrobial pharmacists, CPE pose a major challenge at the bedside as they significantly limit antimicrobial prescribing. 11 Morbidity and mortality are both increased in CPE infections, particularly bloodstream and respiratory infections, 12 with mortality rates ranging from 38-57%, 9 and poor outcomes in survivors, [13] [14] [15] emphasising the need for commencement of timely targeted antimicrobial therapy to increase patient survival.
Culture-based techniques using selective agars for the identification of CPE detect carbapenem-resistant organisms with minimal laboratory 'hands on' bench time, but they cannot differentiate either the carbapenemase type or the Enterobacteriaceae species present with additional phenotypic and/or molecular testing required. 16, 17 Within our laboratory, our current CPE screening process, utilising selective chromogenic agar (CHROMagar™ KPC, Paris, France) and GeneXpert ® Carba-R for in-house molecular confirmation of CPE positive specimens (Cepheid, Buckinghamshire, United Kingdom), had an average turnaround time of 48/72 hours from specimen arrival in the laboratory to final CPE result for the clinician. The 48/72 hour delay in diagnosis was in keeping with other centres worldwide using selective cultures, [18] [19] [20] but was resulting in use of empiric broad-spectrum antimicrobials and an inefficient use of limited isolation facilities. bla VIM and bla NDM) using direct testing from rectal swabs, and has been shown to reduce timeto-diagnosis with good sensitivity and specificity. 22 Previous publications using the Check-Direct CPE ® assay have utilised an automated DNA extraction methodology; NucliSENS ® easyMAG ® extraction kit, bioMérieux, France. [23] [24] [25] To the best of our knowledge, this is the first report of the use of a manual DNA extraction method with the heck-Direct CPE ® assay.
Results

Epidemiological
From 195 anonymised community samples that underwent further processing, 58% (n=112)
were from females. The median age of positive patients was 62.4 years (range 20-94 years).
186 samples (95%) were from general practitioner clinics from patients living in community dwellings. Nine stool samples were received from long-term care facilities (LTCF) of which six were public institutions.
Technical
A significant improvement in time-to-diagnosis versus the existing culture-based processes employed in the laboratory was demonstrated using our newly designed CPE laboratory workflow. The three step process of making the eSwab™, extracting DNA manually and running the Check-Direct CPE® assay, taking <5 minutes, 1 hour 30 minutes, 1 hour 50 minutes respectively, was time efficient with a result available in under 4 hours. A key factor in the ability to provide a result in under 4 hours was no delay in waiting to use the Lightcycler ® instrument. While our process of making the eSwab™ was used as a surrogate for rectal swabs taken from patients, the time taken to perform a rectal swab on a patient is 5-7 minutes following our local standard operating procedure (SOP). When the time taken to transport the rectal swabs from clinical areas to the laboratory is accounted for, usually 10-20 minutes depending on time of day, a CPE results was still possible in under 4 hours.
Antimicrobial susceptibility testing and an Enterobacteriaceae species identification using MALDI-TOF MS is still necessary on any positive isolate identified on the Check-Direct CPE ® assay.
The Check-Direct CPE® assay was able to process larger batches of clinical specimens in comparison to the GeneXpert® Carba-R, making it suitable for use as part of a CPE screening programme. The assay was user-friendly and the interface on the Lightcycler ® was easy to navigate. For clinicians and scientists with no previous or limited PCR experience, the pre-PCR sample preparatory steps required minimal hands-on time, with all steps occurring in an intuitive fashion.
A challenge encountered with our new workflow was that DNA could not be extracted from a number of samples (n=45, 26%) when assessed on the SPECTROstar Nano LVis Plate. This was attributed to a combination of overly diluted samples and other inhibitory factors within the stool specimens such as trace elements of blood in the patient's stool specimen or undigested food particles. Of the 45 stool specimens, 27% (n=12) were recorded as being a liquid consistency on collection, even before dilution. A review of the results from the other 128 community specimens from which DNA was positively extracted displayed a mean DNA concentration of 38.6 ng/µl. Interestingly, 8% (n=10) of these specimens were also classified as having a liquid consistency on collection yet DNA extraction was possible. This was an indication of involvement of other inhibitory factors.
Microbiological
While the aim of this study was not primarily to identify new positive CPE cases, it is worth noting that no positive CPE isolates were detected from culture (n=390 plates; n=195 COLOREX mSuperCARBA ™ , n=195 chromID ® CARBA SMART) following 24 hours incubation. One positive isolate (a KPC) was found using the Check-Direct CPE ® assay as shown in Figure 1 . This specimen had a Ct value of 32.54, which fell within the positive specimen value range.
Discussion
Our aim in performing this study was to design a new laboratory-work flow, utilising existing laboratory physical and human resources, with the aim of expediting the diagnosis of CPE.
The new laboratory work-flow we had designed achieved this objective. A major contributing factor to this improvement in time-to-detection was the use of testing directly from rectal swabs, with the removal of traditional culturing processes, and the ability to perform screening using PCR in larger batches than previously using the GeneXpert ® Carba-R. From a clinical perspective, the old CPE workflow in use within the laboratory was suboptimal as the protracted time to diagnosis was leading to prolonged empiric broad-spectrum antimicrobial use pending CPE screening results, poor patient flow though the hospital, challenges in the allocation of scarce isolation facilities and unnecessary anxiety for patients in awaiting CPE screening results for a minimum of two days.
By removing the use of selective chromogenic screening agar, which are historically labour intensive, with variable sensitivity, 26 this reduced physical work within the laboratory associated with culturing, moving agar plates from incubators to benches for further phenotypic and molecular testing. The availability of physical bench space for other laboratory routine work is also achieved as is the redeployment of scientists from culturing to other tasks.
Rectal swabs are currently considered to be the most sensitive approach to detect colonisation with multi-drug resistant enteric Gram-negatives 8, 27 but are wholly dependent on healthcare workers who are performing rectal swabbing at ward level ensuring the presence of visible faecal staining on the swab, as a surrogate markers for quality/amount of faecal material present, and in turn the likelihood of a good DNA yield on extraction. In this regard, any permanent move to direct testing from rectal swabs would require education to be provided to clinical ward staff. There are of course clinical scenarios where, despite the best efforts of those performing rectal swabs, rectal swabbing can be very challenging, for example, in patients with a large body mass index and those who are highly dependent with minimal independent mobility, it is often a perineum swab that is received. The minimal storage requirements of the eSwab™ makes them a more attractive sampling method also as they are slightly smaller in size than the rectal swabs currently used for screening.
A consideration in selecting a commercial assay for this study was the range of CPE enzyme types detectable and an acceptance that no assay on the market at present has the ability to detect novel carbapenemases or to provide full coverage for all enzyme variants, in particular the OXA-48-like variants. Additionally, no assay as yet can provide an identification to Enterobacteriaceae species level. The most prevalent carbapenemases worldwide are IMP, VIM, OXA-48, NDM and KPC, with the latter three being most commonly identified in
Ireland. 28 The Check-Direct CPE ® assay had the ability to detect and differentiate between bla KPC , bla OXA-48 , bla VIM and bla NDM , the same range as with the current GeneXpert® Carba-R, but the larger volumes of sample that could be processed in each batch was an attractive feature of the Check-Direct CPE ® assay. In 2015, 9493 CPE screens were processed at UHL (average 792 per month), accounting for 20% of the laboratory workload, demonstrating our need for a cost-effective screening solution. A potential future problem that may emerge if the epidemiology of CPE in Ireland changes is that if more IMP isolates begin to appear within the region neither, the Check-Direct CPE ® assay will not have capability to detect these isolates.
From a practical perspective, consideration for the use of an automated DNA extraction method is perhaps warranted given the challenges encountered with the manual DNA extraction. Any extraction method employed must be able to successfully extract DNA from all consistencies of stool specimens for CPE testing.
Conclusions
The accurate and timely detection of CPE is crucial for appropriate patient management and for the rapid implementation of infection prevention and control measures. The integration of a molecular commercial assay for batch CPE screening significantly reduces time-todetection. Changing an existing CPE work-flow must address the potential costs involved, annual numbers of CPE screens processed by the laboratory, CPE gene coverage and whether an automated DNA extraction system can be utilised to ensure optimal results.
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